Breakthrough in new drug development boosts market confidence: Ovid Therapeutics Inc. (NASDAQ: OVID) shares surged 26.4% in pre-market trading today after the company announced positive safety data for its experimental epilepsy drug OV935/TAK-935.

Breakthrough in new drug development boosts market confidence: Ovid Therapeutics Inc. (NASDAQ: OVID) shares surged 26.4% in pre-market trading today after the company announced positive safety data for its experimental epilepsy drug OV935/TAK-935.

老虎证券2026/03/18 10:52

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

This data comes from a Phase II clinical trial targeting patients with developmental and epileptic encephalopathies (DEE). **Significant Progress in Rare Disease Treatment** The released safety data covers the long-term use of the drug in pediatric patients. Developmental and epileptic encephalopathies are a group of rare and severe childhood epilepsy syndromes, with limited treatment options and significant side effects. The drug, co-developed by Ovid and Takeda Pharmaceutical, aims to regulate the glutamate signaling pathway by inhibiting cholesterol 24-hydroxylase, an innovative mechanism in epilepsy treatment. **Biotech Sector Catalysts** The positive data not only boosted Ovid’s stock price but also lifted overall sentiment in the biotechnology sector. Analysts point out that the epilepsy treatment market is expected to reach $9.8 billions by 2028, with a compound annual growth rate of 3.5%. Successfully developing effective therapies for rare epileptic diseases could bring significant commercial value to Ovid. **Next Steps in Clinical Development** Based on these positive results, Ovid plans to discuss the next steps in clinical development with regulatory agencies. CEO Amit Rakhit stated: "These data strengthen our confidence in the safety of OV935/TAK-935 and lay the foundation for subsequent clinical trials." The market is watching whether the drug can enter pivotal Phase III trials and whether Takeda Pharmaceutical will exercise its option to fully take over subsequent development. **Changes in Institutional Investor Holdings** According to the latest disclosed institutional holdings data, several hedge funds have recently increased their positions in Ovid stock. Canaccord Genuity analysts noted in their latest report that if the drug ultimately receives FDA approval, Ovid’s market capitalization could see significant upside, but also cautioned about the inherent risks faced by biotechnology companies during clinical development stages.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

October 9 - ** Shares of Australian Maas Group (MGH.AX) have fallen more than 27% so far this week and are set for their worst weekly performance if the downward trend continues. ** On Thursday, media reported that Firmus, backed by Nvidia, might reduce the size of its AUD 5 billion Australian IPO (link), sparking investor concerns and leading to a 30% plunge in shares of construction services provider MGH. ** MGH holds a 3.2% stake in this AI data center operator. ** MGH suspended trading on Friday (link), pending an announcement related to Firmus. Firmus has shelved its AUD 5 billion listing plan due to market volatility and conditions. ** Before the suspension, MGH's shares had already fallen over 8% this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. This automated translation may contain inaccuracies or omit the desired context; Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no liability for any harm or loss caused by the use of automated translations.)

路透社•2026/10/09 01:26

Apple to launch dual products in October: First touch-screen MacBook and new iPad mini to debut simultaneously

Apple is planning to hold its second product launch event of the month around October 27, where it will introduce its first-ever touchscreen MacBook Pro (featuring an OLED display and the “Dynamic Island” interface), a new iPad mini (also upgraded with OLED and a repositioned camera), as well as a 14-inch MacBook Pro and iMac powered by the M6 chip. These are the first major products overseen by the new CEO, John Ternus.

华尔街见闻•2026/10/09 01:01

BUZZ - Driven by active trading, the Australian Securities Exchange (ASX) is on track for its best week in two months

October 9 – The stock price of ASX ASX.AX, the operator of the Australian Securities Exchange, has risen more than 3.8% so far this week, on track for its best weekly performance since early August. On Thursday, Citi raised its annual earnings per share (EPS) forecast for ASX by 2%, citing continued strong trading activity. On Friday, the stock was up as much as 0.3% to 60.79 AUD. Citi also holds a positive view of ASX’s new CEO, Anthony Attia, agreeing with his approach of bringing in external talent and modernizing technology. Including the latest gain, the stock is up 18% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of the translation. The automated translation is provided solely for the convenience of readers, and Reuters accepts no liability for any damage or loss arising from the use of the automated translation.)

路透社•2026/10/09 00:56